PDCD1 and Miyoshi myopathy: A phase I trial of the anti-PD-1 nivolumab in combination with IMiDs, daratumumab, and proteasome inhibitors uncovered this combined therapy to be effective with a low toxicity profile in highly pretreated and refractory MM patients (149).